Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

PASADENA, Calif., November 07, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion Pharmaceuticals, Inc., on sales of Ultomiris® (ravulizumab-cwvz) and from MorphoSys AG on sales of Monjuvi® (U.S.)/Minjuvi® (ex-U.S.) (tafasitamab-cxix) to OMERS, one of Canada’s largest defined benefit pension plans.

Related Keywords

Canada ,New York ,United States ,Toronto ,Ontario ,Luxembourg ,Sydney ,New South Wales ,Australia ,London ,City Of ,United Kingdom ,Amsterdam ,Noord Holland ,Netherlands ,Singapore ,America ,Monjuvi Minjuvi ,Bassil Dahiyat ,Xencor Xmab ,Charles Liles ,Alexion Pharmaceuticals Inc ,Exchange Commission ,Life Sciences ,Xencor Inc ,Nasdaq ,Alexion Pharmaceuticals ,North America ,Private Securities Litigation Reform Act ,Comers ,Gencor ,Clinical Development ,Iopharmaceutical Company ,Sales Performance ,Treatment Of Cancer ,Autoimmune Diseases ,Nc ,